» Articles » PMID: 24091328

Myeloid-derived Suppressor Cell Development is Regulated by a STAT/IRF-8 Axis

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2013 Oct 5
PMID 24091328
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) comprise immature myeloid populations produced in diverse pathologies, including neoplasia. Because MDSCs can impair antitumor immunity, these cells have emerged as a significant barrier to cancer therapy. Although much research has focused on how MDSCs promote tumor progression, it remains unclear how MDSCs develop and why the MDSC response is heavily granulocytic. Given that MDSCs are a manifestation of aberrant myelopoiesis, we hypothesized that MDSCs arise from perturbations in the regulation of interferon regulatory factor-8 (IRF-8), an integral transcriptional component of myeloid differentiation and lineage commitment. Overall, we demonstrated that (a) Irf8-deficient mice generated myeloid populations highly homologous to tumor-induced MDSCs with respect to phenotype, function, and gene expression profiles; (b) IRF-8 overexpression in mice attenuated MDSC accumulation and enhanced immunotherapeutic efficacy; (c) the MDSC-inducing factors G-CSF and GM-CSF facilitated IRF-8 downregulation via STAT3- and STAT5-dependent pathways; and (d) IRF-8 levels in MDSCs of breast cancer patients declined with increasing MDSC frequency, implicating IRF-8 as a negative regulator in human MDSC biology. Together, our results reveal a previously unrecognized role for IRF-8 expression in MDSC subset development, which may provide new avenues to target MDSCs in neoplasia.

Citing Articles

STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.

Sohrabi S, Alipour S, Ghahramanipour Z, Masoumi J, Baradaran B Bioimpacts. 2025; 15:30030.

PMID: 39963570 PMC: 11830145. DOI: 10.34172/bi.30030.


Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis.

Liao S, Gao X, Zhou K, Kang Y, Ji L, Zhong X Heliyon. 2025; 11(1):e41358.

PMID: 39844989 PMC: 11750479. DOI: 10.1016/j.heliyon.2024.e41358.


Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.

Arleo A, Montagner A, Giovannini C, Suzzi F, Piscaglia F, Gramantieri L Biomolecules. 2025; 14(12.

PMID: 39766202 PMC: 11673139. DOI: 10.3390/biom14121496.


Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells.

Goldmann O, Medina E Front Immunol. 2024; 15:1461455.

PMID: 39534601 PMC: 11554506. DOI: 10.3389/fimmu.2024.1461455.


First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review.

Wang Y, Peng M, Xu Y, Ying Y, Tang L, Xu H Discov Oncol. 2024; 15(1):560.

PMID: 39404967 PMC: 11480291. DOI: 10.1007/s12672-024-01420-3.


References
1.
Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge J, Abe J . Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111(12):5457-66. DOI: 10.1182/blood-2008-01-136895. View

2.
DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

3.
Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden E . Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011; 13(6):591-9. PMC: 3107102. DOI: 10.1093/neuonc/nor042. View

4.
Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

5.
Tamura T, Yanai H, Savitsky D, Taniguchi T . The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008; 26:535-84. DOI: 10.1146/annurev.immunol.26.021607.090400. View